Biotech coalition lobbies for orphan drug exemptions from Medicare price-cut pilots

A coalition of biotech firms is lobbying the Trump administration to exclude orphan drugs from federal pilot programs designed to reduce Medicare drug expenditures. The effort highlights a potential conflict between federal cost-containment initiatives and the financial viability of rare disease drug development.